Literature DB >> 18338717

Study on the factors affecting the MDA programme in Kerala state.

M K Showkath Ali1, R Rajendran, K Regu, M K Mohanan, A C Dhariwal, Shiv Lal.   

Abstract

The Mass Annual Single dose DEC administration (MDA) was initiated in India from 1997. In Kerala MDA was studied as a pilot project in Alappuzha and Kozhikode District from 2000-04 and the first round of MDA was launched in Kerala covering eleven endemic districts, in March 2005. On evaluation, the drug distribution coverage, compliance, etc. were found to be not satisfactory and a need to elicit the factors for poor performance of MDA is felt essential. The main reasons for poor performance of MDA in Kerala state were the lack of adequate prior information to the target population regarding the importance LF elimination programme and inadequate awareness. The fear of side reactions, antipropagonda, poor IEC activities repeated postponement of programme, insufficient time for mobilisation etc. were the other reasons for poor compliance. The purpose of the present study was to bring the observations to the notice of the authorities so that appropriate remedial measures are incorporated.

Mesh:

Substances:

Year:  2007        PMID: 18338717

Source DB:  PubMed          Journal:  J Commun Dis        ISSN: 0019-5138


  3 in total

1.  Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.

Authors:  K D Ramaiah; Eric A Ottesen
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

2.  Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance.

Authors:  Mohammad A Hussain; Ashok K Sitha; Subhashisa Swain; Shridhar Kadam; Sanghamitra Pati
Journal:  Infect Dis Poverty       Date:  2014-09-01       Impact factor: 4.520

Review 3.  A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis.

Authors:  Alison Krentel; Peter U Fischer; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.